Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)

被引:91
作者
Bresler S.C. [1 ,2 ]
Padwa B.L. [3 ,4 ]
Granter S.R. [1 ,2 ]
机构
[1] Department of Pathology, Brigham and Women’s Hospital, 75 Francis St., Boston, 02115, MA
[2] Harvard Medical School, Boston, MA
[3] Department of Plastic and Oral Surgery, Boston Children’s Hospital, Boston, MA
[4] Harvard School of Dental Medicine, Boston, MA
关键词
Basal cell nevus syndrome; Gorlin syndrome; Keratocystic odontogenic tumor; Nevoid basal cell carcinoma syndrome; PTCH1; SMO; SUFU; Vismodegib;
D O I
10.1007/s12105-016-0706-9
中图分类号
学科分类号
摘要
Nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome (Gorlin syndrome), is a rare autosomal dominantly inherited disorder that is characterized by development of basal cell carcinomas from a young age. Other distinguishing clinical features are seen in a majority of patients, and include keratocystic odontogenic tumors (formerly odontogenic keratocysts) as well as dyskeratotic palmar and plantar pitting. A range of skeletal and other developmental abnormalities are also often seen. The disorder is caused by defects in hedgehog signaling which result in constitutive pathway activity and tumor cell proliferation. As sporadic basal cell carcinomas also commonly harbor hedgehog pathway aberrations, therapeutic agents targeting key signaling constituents have been developed and tested against advanced sporadically occurring tumors or syndromic disease, leading in 2013 to FDA approval of the first hedgehog pathway-targeted small molecule, vismodegib. The elucidation of the molecular pathogenesis of nevoid basal cell carcinoma syndrome has resulted in further understanding of the most common human malignancy. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:119 / 124
页数:5
相关论文
共 33 条
[21]  
Reifenberger J., Wolter M., Knobbe C.B., Kohler B., Schonicke A., Scharwachter C., Et al., Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas, Br J Dermatol, 152, pp. 43-51, (2005)
[22]  
Evans D.G., Ladusans E.J., Rimmer S., Burnell L.D., Thakker N., Farndon P.A., Complications of the naevoid basal cell carcinoma syndrome: results of a population based study, J Med Genet, 30, pp. 460-464, (1993)
[23]  
Bree A.F., Shah MR for the BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS), Am J Med Genet Part A, 155, pp. 2091-2097, (2011)
[24]  
Parren L.J.M.T., Frank J., Hereditary tumour syndromes featuring basal cell carcinomas, Br J Dermatol, 165, pp. 30-34, (2011)
[25]  
Abuzahra F., Parren L.J., Frank J., Multiple familial and pigmented basal cell carcinomas in early childhood - Bazex-Dupre-Christol syndrome, J Eur Acad Dermatol Venereol, 26, pp. 117-121, (2012)
[26]  
Parren L.J.M.T., Abuzahra F., Wagenvoort T., Koene F., Van Steensel M.A.M., Steijlen P.M., Et al., Linkage refinement of Bazex-Dupré-Christol syndrome to an 11·4-Mb interval on chromosome Xq25-27.1, Br J Dermatol, 165, pp. 201-203, (2011)
[27]  
Karagas M.R., Zens M.S., Li Z., Stukel T.A., Perry A.E., Gilbert-Diamond D., Et al., Early-onset basal cell carcinoma and indoor tanning: a population-based study, Pediatrics, 134, pp. e4-e12, (2014)
[28]  
Woo S.-B., Oral pathology: a comprehensive atlas and text, (2012)
[29]  
Gurgel C.A.S., Ramos E.A.G., Azevedo R.A., Sarmento V.A., da Silva Carvalho A.M., dos Santos J.N., Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study, J Mol Histol, 39, pp. 311-316, (2008)
[30]  
Henley J., Summerlin D.-J., Tomich C., Zhang S., Cheng L., Molecular evidence supporting the neoplastic nature of odontogenic keratocyst: a laser capture microdissection study of 15 cases, Histopathology, 47, pp. 582-586, (2005)